Sylvia E. Escher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sylvia E. Escher has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
I. Mangelsdorf
Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Str. 1, Hannover, Germany
4 shared publications- Vera Rogiers
Department of In Vitro Toxicology and Dermato-Cosmetology (IVTD), Vrije Universiteit Brussel, Brussels, Belgium
4 shared publications - Andreas Karwath
College of Medicine and Health, School of Medical Sciences, University of Birmingham, Birmingham, UK
3 shared publications - Bob van de Water
Leiden University, Leiden Academic Centre for Drug Research, Division of Cell Systems and Drug Safety, Leiden, The Netherlands
3 shared publications M. Batke
Fraunhofer Institute for Toxicology and Experimental Medicine, Nikolai-Fuchs-Str. 1, Hannover, Germany
3 shared publicationsA. Bitsch
Fraunhofer Institute for Toxicology and Experimental Medicine (Item)
2 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (10) , 4717-4736
The in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines
N -nitrosamine (NA) impurities in pharmaceuticals represent “cohort of concern” compounds under ICH M7(R2), due to their mutagenic/carcinogenic potential, involving cytochrome P450 (CYP)-mediated metabolic activation. Increasing interest in mammalian cell-based genotoxicity/mutagenicity assays prompted our assessment of the in vitro alkaline comet assay regarding its predictive power for NAs. Here, precision-cut liver slices (PCLiS), primary human hepatocytes (PHH), primary rat hepatocytes (PRH), and HepG2 cells with rat or hamster S9-mix were investigated as in vitro model systems. Metabolic competence was characterized beforehand. For performance evaluation, a panel of known-mutagenic [ N -nitroso-dimethylamine (NDMA), N -nitroso-diethanolamine, N -nitroso-methylaniline, S – N -nitroso-nornicotine, N-methyl-N-nitroso-2-propanamine] and reported non-mutagenic (methyl-t-butylnitrosamine, N -nitrosoproline) was tested, together with Nitrosamine Drug Substance-Related Impurities [ N -nitrosodesloratadine, N -nitrosofolic acid, N -nitrosofluoxetine (NFluo)] at a concentration range of 0.005–10 mM. After 2 h (PCLiS, PHH and PRH) or 4 h (HepG2), NDMA concentration-dependently induced DNA strand breaks in all in vitro models. Sensitivity/specificity of the various liver cell models for prediction of carcinogenic NAs were 100%/50% (HepG2 with hamster S9-mix), 50%/100% (PHH, PRH), and 50%/50% (HepG2 with rat S9-mix), respectively. Benchmark dose modeling indicated a higher relative in vitro comet assay response for NFluo compared to NDMA in all cell systems. In conclusion, the in vitro comet assay represents a sensitive and/or specific tool for complementing regulatory in vitro tests in prediction of mutagenic NAs. However, further optimization work is needed, using expanded training sets of compounds and thorough validation of liver cell models, before the in vitro comet assay could be incorporated in the standard battery for genotoxicity testing.
- 2 June 2026
- Published by Springer Nature in Archives of Toxicology
- Vol. 100 (10) , 4717-4736
Open AccessThe in vitro alkaline comet assay with liver models as a complementary tool for genotoxicity assessment of N-nitrosamines
N -nitrosamine (NA) impurities in pharmaceuticals represent “cohort of concern” compounds under ICH M7(R2), due to their mutagenic/carcinogenic potential, involving cytochrome P450 (CYP)-mediated metabolic activation. Increasing interest in mammalian cell-based genotoxicity/mutagenicity assays prompted our assessment of the in vitro alkaline comet assay regarding its predictive power for NAs. Here, precision-cut liver slices (PCLiS), primary human hepatocytes (PHH), primary rat hepatocytes (PRH), and HepG2 cells with rat or hamster S9-mix were investigated as in vitro model systems. Metabolic competence was characterized beforehand. For performance evaluation, a panel of known-mutagenic [ N -nitroso-dimethylamine (NDMA), N -nitroso-diethanolamine, N -nitroso-methylaniline, S – N -nitroso-nornicotine, N-methyl-N-nitroso-2-propanamine] and reported non-mutagenic (methyl-t-butylnitrosamine, N -nitrosoproline) was tested, together with Nitrosamine Drug Substance-Related Impurities [ N -nitrosodesloratadine, N -nitrosofolic acid, N -nitrosofluoxetine (NFluo)] at a concentration range of 0.005–10 mM. After 2 h (PCLiS, PHH and PRH) or 4 h (HepG2), NDMA concentration-dependently induced DNA strand breaks in all in vitro models. Sensitivity/specificity of the various liver cell models for prediction of carcinogenic NAs were 100%/50% (HepG2 with hamster S9-mix), 50%/100% (PHH, PRH), and 50%/50% (HepG2 with rat S9-mix), respectively. Benchmark dose modeling indicated a higher relative in vitro comet assay response for NFluo compared to NDMA in all cell systems. In conclusion, the in vitro comet assay represents a sensitive and/or specific tool for complementing regulatory in vitro tests in prediction of mutagenic NAs. However, further optimization work is needed, using expanded training sets of compounds and thorough validation of liver cell models, before the in vitro comet assay could be incorporated in the standard battery for genotoxicity testing.
- Open Access
- 4 October 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2173-2185
A Unified Whole Lung PBK Model for Inhalational Uptake of Gases and Aerosols in Men
Assessing the risk or benefit of an inhaled substance is challenging due to the variety of forms it can take (gas, vapor, particle, or droplet) and the complex biological processes involved in its uptake and retention. Physiologically based kinetic (PBK) models offer an alternative to in vivo experiments. However, PBK models for inhalational uptake are to date either designed for gases/vapors or airborne particulates, often with only low regional compartmentalization. The here‐presented, newly developed model combines both applications. Its mechanisms are an amalgamation of PBK and non‐PBK models integrated into a multicompartmental description of the human lung to include the relevant uptake and clearance processes in the different lung regions, of which macrophage‐mediated dissolution is novel to PBK modeling. The model was designed to use a minimal number of substance‐specific input parameters, which can be derived from in vitro assays or in silico methods. Model predictions for hypothetical substances with varying physicochemical properties were performed, along with rudimentary sensitivity analyses to identify the most important parameters for gases/vapors and particles. This novel PBK model combines all these aspects and provides in silico predictions of systemic and local lung concentrations, reducing uncertainty in risk assessments and supporting drug development. It serves as a valuable tool to translate nominal ambient air doses into effective localized doses within the lung.
- 4 October 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2173-2185
Open AccessA Unified Whole Lung PBK Model for Inhalational Uptake of Gases and Aerosols in Men
Assessing the risk or benefit of an inhaled substance is challenging due to the variety of forms it can take (gas, vapor, particle, or droplet) and the complex biological processes involved in its uptake and retention. Physiologically based kinetic (PBK) models offer an alternative to in vivo experiments. However, PBK models for inhalational uptake are to date either designed for gases/vapors or airborne particulates, often with only low regional compartmentalization. The here‐presented, newly developed model combines both applications. Its mechanisms are an amalgamation of PBK and non‐PBK models integrated into a multicompartmental description of the human lung to include the relevant uptake and clearance processes in the different lung regions, of which macrophage‐mediated dissolution is novel to PBK modeling. The model was designed to use a minimal number of substance‐specific input parameters, which can be derived from in vitro assays or in silico methods. Model predictions for hypothetical substances with varying physicochemical properties were performed, along with rudimentary sensitivity analyses to identify the most important parameters for gases/vapors and particles. This novel PBK model combines all these aspects and provides in silico predictions of systemic and local lung concentrations, reducing uncertainty in risk assessments and supporting drug development. It serves as a valuable tool to translate nominal ambient air doses into effective localized doses within the lung.
- Open Access
- 28 February 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 159, 105796
Report on the European Partnership for Alternative Approaches to Animal Testing (EPAA) “New Approach Methodologies (NAMs) User Forum Kick-Off Workshop”
- 28 February 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 159, 105796
Open AccessReport on the European Partnership for Alternative Approaches to Animal Testing (EPAA) “New Approach Methodologies (NAMs) User Forum Kick-Off Workshop”
- Open Access
- 1 January 2025
- Published by ALTEX Edition in ALTEX
Estimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling
N-nitrosamines (NAs) are potentially carcinogenic organic compounds, and nitrosamine drug substance-related impurities (NDSRIs) are currently regulated with class-specific thresholds in the low nanogram range according to the carcinogenic potency categorization approach (CPCA) classification schema. Beyond direct exposure, NDSRIs can form endogenously in the human organism after ingestion of secondary amines. As recently shown, enalapril, propranolol, and fluoxetine form NDSRIs under conditions mimicking the acidic environment in the stomach. The MUTAMIND project investigated whether such endogenously formed NA levels lead to plasma or liver concentrations which align with or exceed the acceptable intake limits based on the current CPCA. A generic physiologically based kinetic (PBK) model was built using compound-specific in vitro ADME parameters such as intestinal permeability and hepatic clearance. The predictions correlated well with measured in vivo ADME data for the data-rich APIs, so the same PBK approach was applied to the corresponding NDSRIs. While the modelling of propranolol was unremarkable, the highest NA conversion rate observed for N-nitrosoenalapril under gastric conditions resulted in plasma and liver levels exceeding those derived from the CPCA threshold by a factor of about 800 and 400, respectively. The long half-life of fluoxetine suggests a risk of bioaccumulation of its nitrosamine with chronic exposure. These findings indicate that PBK modelling could be a valuable tool as part of a weight of evidence approach in contributing to the risk assessment of nitrosamine impurities in pharmaceuticals. Plain language summaryExposure to N-nitrosamines (NAs) can occur through direct oral uptake of NAs or formation of NAs from certain compounds in the body and is potentially harmful. NAs are regulated by the Carcinogenic Potency Category Approach (CPCA), which establishes acceptable intake based on chemical structure properties and corresponding animal studies. In vitro experiments combined with physiologically based kinetic (PBK) modeling enables us to model the levels of NAs reached in the human body over time. We have incorporated data on the formation of NAs from certain drugs in artificial stomach acid into the PBK model and compared the levels that can be reached to CPCA thresholds. We show that PBK models based on species- and substance-specific data serve as a suitable tool for assessing internal exposure without animal experimentation.
- 1 January 2025
- Published by ALTEX Edition in ALTEX
Open AccessEstimation of bioavailable concentration of endogenously formed N-nitrosamines by physiologically based kinetic modelling
N-nitrosamines (NAs) are potentially carcinogenic organic compounds, and nitrosamine drug substance-related impurities (NDSRIs) are currently regulated with class-specific thresholds in the low nanogram range according to the carcinogenic potency categorization approach (CPCA) classification schema. Beyond direct exposure, NDSRIs can form endogenously in the human organism after ingestion of secondary amines. As recently shown, enalapril, propranolol, and fluoxetine form NDSRIs under conditions mimicking the acidic environment in the stomach. The MUTAMIND project investigated whether such endogenously formed NA levels lead to plasma or liver concentrations which align with or exceed the acceptable intake limits based on the current CPCA. A generic physiologically based kinetic (PBK) model was built using compound-specific in vitro ADME parameters such as intestinal permeability and hepatic clearance. The predictions correlated well with measured in vivo ADME data for the data-rich APIs, so the same PBK approach was applied to the corresponding NDSRIs. While the modelling of propranolol was unremarkable, the highest NA conversion rate observed for N-nitrosoenalapril under gastric conditions resulted in plasma and liver levels exceeding those derived from the CPCA threshold by a factor of about 800 and 400, respectively. The long half-life of fluoxetine suggests a risk of bioaccumulation of its nitrosamine with chronic exposure. These findings indicate that PBK modelling could be a valuable tool as part of a weight of evidence approach in contributing to the risk assessment of nitrosamine impurities in pharmaceuticals. Plain language summaryExposure to N-nitrosamines (NAs) can occur through direct oral uptake of NAs or formation of NAs from certain compounds in the body and is potentially harmful. NAs are regulated by the Carcinogenic Potency Category Approach (CPCA), which establishes acceptable intake based on chemical structure properties and corresponding animal studies. In vitro experiments combined with physiologically based kinetic (PBK) modeling enables us to model the levels of NAs reached in the human body over time. We have incorporated data on the formation of NAs from certain drugs in artificial stomach acid into the PBK model and compared the levels that can be reached to CPCA thresholds. We show that PBK models based on species- and substance-specific data serve as a suitable tool for assessing internal exposure without animal experimentation.
- Open Access
- 26 August 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 144, 105483
Exposure considerations in human safety assessment: Report from an EPAA Partners’ Forum
- 26 August 2023
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 144, 105483
Open AccessExposure considerations in human safety assessment: Report from an EPAA Partners’ Forum
- Open Access
- 1 March 2022
- Published by Elsevier in Toxicology in Vitro
- Vol. 79, 105269
Integrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action
- 1 March 2022
- Published by Elsevier in Toxicology in Vitro
- Vol. 79, 105269
Open AccessIntegrate mechanistic evidence from new approach methodologies (NAMs) into a read-across assessment to characterise trends in shared mode of action
- Open Access
- 1 February 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 128, 105089
RespiraTox – Development of a QSAR model to predict human respiratory irritants
- 1 February 2022
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 128, 105089
Open AccessRespiraTox – Development of a QSAR model to predict human respiratory irritants
- Open Access
- 31 January 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (3) , 945-946
Correction to: Toxicogenomics directory of chemically exposed human hepatocytes
- 31 January 2022
- Published by Springer Nature in Archives of Toxicology
- Vol. 96 (3) , 945-946
Open AccessCorrection to: Toxicogenomics directory of chemically exposed human hepatocytes
- Open Access
- 1 January 2022
- Published by ALTEX Edition in ALTEX
- Vol. 40 (2) , 341-349
Workshop report on the evaluation of the updated and expanded carcinogen database to support derivation of threshold of toxicological concern values for DNA reactive carcinogens
Threshold of toxicological concern (TTC) values are frequently used for compounds occurring at low concentrations in feed and food or as impurities in drugs. This workshop report addresses the emerging alternatives for deriving TTC values for DNA reactive carcinogens and evaluating the acceptability of the Cramer Class TTC values to be adequately protective for non-DNA reactive carcinogens.
- 1 January 2022
- Published by ALTEX Edition in ALTEX
- Vol. 40 (2) , 341-349
Open AccessWorkshop report on the evaluation of the updated and expanded carcinogen database to support derivation of threshold of toxicological concern values for DNA reactive carcinogens
Threshold of toxicological concern (TTC) values are frequently used for compounds occurring at low concentrations in feed and food or as impurities in drugs. This workshop report addresses the emerging alternatives for deriving TTC values for DNA reactive carcinogens and evaluating the acceptability of the Cramer Class TTC values to be adequately protective for non-DNA reactive carcinogens.
- 26 September 2021
- Published by Springer Nature
- p. 525-538
Read-Across Methodology in Toxicological Risk Assessment
- 26 September 2021
- Published by Springer Nature
- p. 525-538
Read-Across Methodology in Toxicological Risk Assessment